Study guide

9.3 Causality, Expectedness and Reference Safety Information

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

9.3 Causality, Expectedness and Reference Safety Information

Key Takeaways Explain This Topic AI

Preserve investigator and sponsor assessments when causality opinions differ.

E2A treats reasonable causal suspicion by either reporting clinician or sponsor as relevant for ADR reporting.

A mild listed reaction does not automatically make a much more severe presentation expected.

Last updated: October 2026

Causality, Expectedness and Reference Safety Information

Investigators and medical monitors evaluate several clinical dimensions:

Temporal Sequence: Did the adverse event emerge after administration of the investigational product? Did it occur within a plausible pharmacokinetic/pharmacodynamic window?

Dechallenge: Does the adverse event subside, improve, or completely resolve when the investigational product is temporarily stopped or discontinued? (Positive dechallenge).

Rechallenge: Does the adverse event re-emerge or worsen if the investigational product is re-introduced? (Positive rechallenge).

Underlying Medical Condition: Can the event be fully explained by the natural history or progression of the participant's pre-existing disease?

Concomitant Medications: Could a concomitant prescription drug, over-the-counter medicine, herbal supplement, or diagnostic procedure be the primary etiological factor?

Known Pharmacological Mechanism: Is the event consistent with the receptor binding, metabolic pathways, or toxicology documented in nonclinical animal studies or the Investigator's Brochure?

Investigator vs. Sponsor Causality: The Non-Downgrade Rule

Both the Principal Investigator and the trial sponsor perform independent causality assessments. However, strict international harmonization rules govern how disagreements are handled:

Important

The Non-Downgrade Mandate: Under ICH GCP and international regulatory reporting standards, the sponsor may never downgrade an investigator's causality assessment to avoid expedited reporting.

If the Principal Investigator determines that an SAE has a "reasonable possibility" of being related to the investigational product (causality = Related), the sponsor must treat the event as an Adverse Reaction for regulatory reporting purposes, even if the sponsor's medical monitor strongly believes the event is completely unrelated.

If the Principal Investigator evaluates an event as "Unrelated," but the sponsor's medical monitor evaluates it as "Related," the sponsor must report the event as related .

In summary: If either the investigator OR the sponsor considers the event reasonably possibly related to the IMP, the event is classified as related for expedited regulatory reporting! The sponsor may record its differing opinion in the safety report narrative, but it cannot override the investigator's assessment to suppress expedited submission.

Expectedness and the Reference Safety Information (RSI)

Once an adverse event is determined to be serious and related (a Serious Adverse Reaction, or SAR), the next determination is expectedness . Expectedness dictates whether the event requires expedited notification to health authorities.

What is the Reference Safety Information (RSI)?

The Reference Safety Information (RSI) is the official regulatory baseline document that details all known, expected adverse reactions associated with the investigational medicinal product.

In clinical trials of investigational drugs, the RSI is located in the designated part of the applicable IB.

For trials utilizing commercially authorized drugs within their licensed indications, the approved Summary of Product Characteristics (SmPC) or local Package Insert serves as the RSI.

Use the applicable, version-controlled RSI and relevant requirements; do not assume one fixed IB section number.

Criteria for Determining Unexpectedness

An adverse event is categorized as unexpected if:

It is not listed in the approved Reference Safety Information at all.

It is listed, but the severity or specificity of the observed event is greater than what is documented in the RSI (e.g., RSI describes mild reversible skin rash; participant experiences toxic epidermal necrolysis).

The event has a fatal or life-threatening outcome, whereas the RSI lists only non-fatal occurrences of the reaction.

It reflects a class effect known for similar drugs, but has not yet been specifically observed or listed for the trial drug in its approved RSI.

Comprehensive Safety Classification Comparison Matrix

To synthesize these regulatory constructs, review the following comparative matrix detailing clinical scenarios and their regulatory classifications:

Term Abbreviation Core Definition Causal Relationship Required? Regulatory Action Triggered Realistic Clinical Scenario Example

Adverse Event AE Any untoward medical occurrence in a study subject; temporal association only. No. Causality not required; can be unrelated. Recorded on source documents and routine eCRF AE log; monitored during IMVs. A participant trips over a garden hose, fracturing their left wrist. Recorded as a moderate AE; with seriousness assessed separately, including medically important events.

Serious Adverse Event SAE Any AE resulting in death, immediate life threat, hospitalization, disability, congenital anomaly, or medical intervention. No. Evaluated regardless of causality (related or unrelated). Immediate, subject to protocol-defined exceptions reporting to sponsor; recorded on SAE form. A participant is admitted to the hospital overnight for acute bacterial pneumonia. Classified as an SAE due to inpatient hospitalization, regardless of whether pneumonia is drug-related.

Adverse Drug Reaction ADR / AR Any noxious and unintended response to an investigational product at any dose. Yes. At least a "reasonable possibility" of causal relationship. Recorded as an AE/ADR on eCRF; reviewed for cumulative safety signal surveillance. A participant develops severe nausea and dry mouth 45 minutes after taking the oral investigational product, resolving upon washout.

Suspected Unexpected Serious Adverse Reaction SUSAR An adverse reaction that is simultaneously Serious , Suspected related , and Unexpected per the RSI. Yes. Suspected causal relationship evaluated by investigator or sponsor. Triggers mandatory expedited regulatory reporting (7 calendar days for fatal/life-threatening; 15 days for others). A participant receiving an investigational kinase inhibitor develops acute Stevens-Johnson Syndrome requiring ICU admission; SJS is not listed in the current RSI.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E2A , WMA Declaration of Helsinki, 2024 .